Molecular basis for hypertension in the 'type II variant' of apparent mineralocorticoid excess

American Journal of Human Genetics

Volumn 63, Issue 2, 1998, Pages 370-379

  Li, A ^a   Tedde, R ^b   Krozowski, Z S ^c   Pala, A ^b   Li, K X Z ^c   Shackleton, C H L ^d   Mantero, F ^e   Palermo, M ^b   Stewart, P M ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF SASSARI   (Italy)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^d CHILDREN S HOSPITAL OAKLAND   (United States)

^e UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; CORTISONE; HYDROCORTISONE; MINERALOCORTICOID;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE CLASSIFICATION; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; GENETIC LINKAGE; HUMAN; HYPERTENSION; MALE; POINT MUTATION; PRIORITY JOURNAL; STEROID METABOLISM;

EID: 0032231654     PISSN: 00029297     EISSN: None     Source Type: Journal    
DOI: 10.1086/301955     Document Type: Article

References (43)

1. Albiston AL, Obeyesekere VR, Smith RE, Krozowski ZS (1994) Cloning and tissue distribution of the human 11β-hydroxysteroid dehydrogenase type 2 enzyme. Mol Cell Endocrinol 105:R11-R17
2. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Houseman DE, Evans RM (1987) Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237:268-275
3. Dimartino-Nardi J, Stoner E, Martin K, Balfe JW, Jose PA, New MI (1987) New findings in apparent mineralocorticoid excess. Clin Endocrinol (Oxf) 27:49-62
4. Edwards CRW, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, de Kloet ER, et al (1988) Localization of 11β-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet 2:986-989
5. Farese RV, Bigheri EG, Shackleton CHL, Irony I, Gomez-Fontes R (1991) Licorice-induced hypermineralocorticoidism. N Engl J Med 325:1223-1227
6. Ferrari P, Obeyesekere VR, Li K, Wilson RC, New MI, Funder JW, Krozowski ZS (1996) Point mutations abolish 11β-hydroxysteroid dehydrogenase type 2 activity in three families with the congenital syndrome of apparent mineralocorticoid excess. Mol Cell Endocrinol 119:21-24
7. Funder JW, Pearce PT, Smith R, Smith AI (1988) Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 242:583-585
8. Gordon RD (1995) Heterogenous hypertension. Nat Genet 11: 6-9
9. Krozowski Z, Funder JW (1983) Renal mineralocorticoid receptors and hippocampal corticosterone-binding sites have identical intrinsic steroid specificity. Proc Natl Acad Sci USA 80:6056-6060
10. Li A, Li KXZ, Marui S, Krozowski ZS, Batista MC, Whorwood CB, Arnhold IJP, et al (1997) Apparent mineralocorticoid excess in a Brazilian kindred: hypertension in the heterozygote state. J Hypertens 15:1397-1402
11. Mantero F, Palermo M, Petrelli MD, Tedde R, Stewart PM, Shackleton CHL (1996) Apparent mineralocorticoid excess: type I and type II. Steroids 61:193-196
12. Mantero F, Tedde R, Opocher G, Fulgheri P, Arnaldi G, Ulick S (1994) Apparent mineralocorticoid excess type II. Steroids 59:80-83
13. Monder C, Shackleton CHL, Bradlow HL, New MI, Stoner E, Iohan F, Lakshmi V (1986) The syndrome of apparent mineralocorticoid excess: its association with 11β-dehydrogenase and 5β-reductase deficiency and some consequences for corticosteroid metabolism. J Clin Endocrinol Metab 63:550-557
14. Mune T, Rogerson FM, Nikkila H, Agarwal AK, White PC (1995) Human hypertension caused by mutations in the kidney isozyme of 11β-hydroxysteroid dehydrogenase. Nat Genet 10:394-399
15. Mune T, White PC (1996) Apparent mineralocorticoid excess: genotype is correlated with biochemical phenotype. Hypertension 27:1193-1199
16. Nikkilä H, Tannin GM, New MI, Taylor NF, Kalaitzoglou G, Monder C, White PC (1993) Defects in the HSD11 gene encoding 11β-hydroxysteroid dehydrogenase are not found in patients with apparent mineralocorticoid excess or 11-oxoreductase deficiency. J Clin Endocrinol Metab 77: 687-691
17. Oberfield SE, Levine LS, Carey RM, Greig F, Ulick S, New MI (1983) Metabolic and blood pressure responses to hydrocortisone in the syndrome of apparent mineralocorticoid excess. J Clin Endocrinol Metab 56:332-338
18. Obeyesekere VR, Ferrari P, Andrews RK, Wilson RC, New MI, Funder JW, Krozowski ZS (1995) The R337C mutation generates a high Km 11β-hydroxysteroid dehydrogenase type II enzyme in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab 80:3381-3383
19. Palermo M, Shackleton CHL, Mantero F, Stewart PM (1996) Urinary free cortisone and the assessment of 11β-hydroxysteroid dehydrogenase activity in man. Clin Endocrinol (Oxf) 45:605-611
20. Phillipou G (1982) Investigation of urinary steroid profiles as a diagnostic method in Cushing's syndrome. Clin Endocrinol (Oxf) 16:433-439
21. Shackleton CHL (1993) Mass spectrometry in the diagnosis of steroid-related disorders and in hypertensive research. J Steroid Biochem Mol Biol 45:127-140
22. Shackleton CHL, Rodriguez J, Arteaga E, Lopez JM, Winter JSD (1985) Congenital 11β-hydroxysteroid dehydrogenase deficiency associated with juvenile hypertension: corticosteroid metabolite profiles of four patients and their families. Clin Endocrinol (Oxf) 22:701-712
23. Shackleton CHL, Stewart PM (1990) The hypertension of apparent mineralocorticoid excess (AME) syndrome. In: Biglieri EG, Melby JE (eds) Endocrine hypertension. Raven Press, New York, pp 155-173
24. Shimojo M, Ricketts ML, Petrelli M, Moradi P, Johnson GD, Bradwell AP, Hewison M, et al (1997) Immunodetection of 11β-hydroxysteroid dehydrogenase type 2 in human mineralocorticoid tissues: evidence for nuclear localization. Endocrinology 138:1305-1311
25. Shimojo M, Stewart PM (1995) Apparent mineralocorticoid excess syndromes. J Endocrinol Invest 18:518-532
26. Simard J, Rheaume E, Mebarki F, Sanchez R, New MI, Morel Y, Labrie F (1995) Molecular basis of human 3β-hydroxysteroid dehydrogenase deficiency. J Steroid Biochem Mol Biol 53:127-138
27. Soro A, Ingram MC, Tonolo G, Glorioso N, Fraser R (1995) Evidence of coexisting changes in 11β-hydroxysteroid dehydrogenase and 5β-reductase activity in patients with untreated essential hypertension. Hypertension 25:67-70
28. Stewart PM, Corrie JET, Shackleton CHL, Edwards CRW (1988) Syndrome of apparent mineralocorticoid excess: a defect in the cortisol-cortisone shuttle. J Clin Invest 82: 340-349
29. Stewart PM, Krozowski ZS, Gupta A, Milford DV, Howie AJ, Sheppard MC, Whorwood CB (1996) Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11β-hydroxysteroid dehydrogenase type 2 gene. Lancet 347:88-91
30. Stewart PM, Murry BA, Mason JI (1994a) Human kidney 11β-hydroxysteroid dehydrogenase is a high affinity nicotinamide adenine dinucleotide-dependent enzyme and differs from the cloned type 1 isoform. J Clin Endocrinol Metab 79:480-484
31. Stewart PM, Murry BA, Mason JI (1994b) Type 2 11β-hydroxysteroid dehydrogenase in human fetal tissues. J Clin Endocrinol Metab 78:1529-1532
32. Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CHL, Edwards CRW (1987) Mineralocorticoid activity of liquorice: 11β-hydroxysteroid dehydrogenase comes of age. Lancet 2:821-824
33. Tannin GM, Agarwal AK, Monder C, New MI, White PC (1991) The human gene for 11β-hydroxysteroid dehydrogenase: structure, tissue distribution and chromosomal localization. J Biol Chem 266:16653-16658
34. Tedde R, Pala A, Melis A, Ulick S (1992) Evidence for cortisol as the mineralocorticoid in the syndrome of apparent mineralocorticoid excess. J Endocrinol Invest 15:471-474
35. Ulick S, Levine LS, Gunczler P, Zanconato G, Ramirez LC, Rauh W, Rosler A, et al (1979) A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. J Clin Endocrinol Metab 49:757-764
36. Ulick S, Tedde R, Mantero F (1990) Pathogenesis of the type 2 variant of the syndrome of apparent mineralocorticoid excess. J Clin Endocrinol Metab 70:200-206
37. Ulick S, Tedde R, Wang ZJ (1992) Defective ring A reduction of cortisol as the major metabolic error in the syndrome of apparent mineralocorticoid excess. J Clin Endocrinol Metab 74:593-599
38. Werder E, Zachmann M, Vollmin JA, Veyrat R, Prader A (1974) Unusual steroid excretion in a child with low renin hypertension. Res Steroid 6:385-389
39. White PC, Mune T, Agarwal A (1997) 11β-Hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocr Rev 18:135-156
40. Whorwood CB, Mason JI, Ricketts ML, Howie AJ, Stewart PM (1995) Detection of human 11β-hydroxysteroid dehydrogenase isoforms using RT-PCR and localization of the type 2 isoform to renal collecting ducts. Mol Cell Endocrinol 110:R7-R12
41. Wilson RC, Dave-Sharma S, Wei JQ, Obeyesekere VR, Li K, Ferrari P, Krozowski ZS, et al (1997) A new mild form of apparent mineralocorticoid excess. In: Proceedings of the 79th annual meeting of the Endocrine Society OR3-1 (abstract)
42. Wilson RC, Harbison MD, Krozowski ZS, Funder JW, Shackleton CHL, Hanauske-Abel HM, Wei JQ, et al (1995a) Several homozygous mutations in the gene for 11β-hydroxysteroid dehydrogenase type 2 in patients with apparent mineralocorticoid excess. J Clin Endocrinol Metab 80: 3145-3150
43. Wilson RC, Krozowski ZS, Li K, Obeyesekere VR, Razzaghy-Azar M, Harbison MD, Wei JQ, et al (1995b) A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab 80:2263-2266